

**From:** Wood, Lorraine  
**Sent:** Tuesday, April 17, 2018 1:51 PM  
**To:** 'MaryAnn Lamb' <MaryAnn.Lamb@bpl-us.com>  
**Subject:** Name Suffix Request for BLA 125644: Response Requested by May 1 2018  
**Importance:** High

Dear Dr. Lamb,

According to the attached FDA Guidance Document ***Nonproprietary Naming of Biological Products***, applicants for products submitted for a Biologics License Application (BLA) should propose a suffix to their biological product proper name composed of four lowercase letters, for use as the distinguishing identifier included in the proper name designated by the FDA at the time of licensure. Applicants should submit up to 10 proposed suffixes as described in section VI of the Guidance document.

Please submit the proposed suffixes for Human Albumin Solution (HAS) 5% and 25% as an amendment to BLA 125644 by May 1, 2018. Please review the attach guidance document for more information and contact me if you have any questions.

Thank you  
Lorraine

**Lorraine D. Wood, MS, MLS(ASCP)<sup>CM</sup>**  
*Regulatory Project Manager*

Center for Biologics Evaluation and Research  
Office of Blood Research and Review  
U.S. Food and Drug Administration  
Tel: 240-402-8439  
[lorraine.wood@fda.hhs.gov](mailto:lorraine.wood@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.